Industry News

Humana Inc. received Well-being Top Honors in Washington, D.C., this week as one of the top five companies among all national applicants for the Best Employers for Healthy Lifestyles ® award, given by the National Business Group on Health to recognize organizations with the best workforce well-being programs in the U.S."/>
Humana’s Workplace Well-being Efforts Honored as Being among the Best in the Nation
BioMarin Pharmaceutical Inc. announced today that the European Medicines Agency validated the Marketing Authorization Application for Brineura™ to treat children with CLN2 disease, a form of Batten disease. Validation of the MAA confirms that the submission is accepted and starts the formal review process by the EMA's Committee for Human Medicinal Products.. Earlier this year, the CHMP accepted BioMarin's request for accelerated assessment..."/>
BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
Pfizer Inc. today announced that a Phase 3 study of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint. Both 5 mg and 15 mg daily doses of..."/>
Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
MRI Interventions, Inc., the leader in Neuro Navigation utilizing intraoperative MRI guidance, today announced that Frank Grillo, President and CEO, will present at two upcoming investor conferences:. The 2016 Aegis Growth Conference being held at The Encore at Wynn Las Vegas in Las Vegas, Nevada, September 20-22; and The MicroCap Plus Conference, being held at the Hotel Monaco in Philadelphia, October 24 and 25.. Grillo’ s presentation may be accessed on the..."/>
MRI Interventions to Present at Upcoming Investor Conferences
TapImmune Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1- for-12 reverse stock split of the Company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its..."/>
TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today that it will present at the 2016 Aegis Growth Conference in Las Vegas, NV, on Thursday, September 22, 2016, at the Encore at Wynn Las Vegas.. William J. Caragol, PositiveID's Chairman and CEO, will provide an update on PositiveID's molecular diagnostics business including its Firefly Dx real-time pathogen detection system; E-N-G Mobile Systems, its..."/>
PositiveID Corporation to Present at the 2016 Aegis Growth Conference on September 22nd
WellCare Health Plans, Inc., donated $2,400 to Louisville Grows, an urban agriculture and education nonprofit, to support its urban farming outreach efforts."/>
WellCare Builds on Commitments to Strengthen Food Security
First Choice Healthcare Solutions, Inc., one of the nation's only non-physician-owned, publicly traded healthcare services companies focused on Orthopaedic and Spine care, is pleased to announce that the Company has been invited to present at the inaugural MicroCap Leadership Summit to be held next week on Friday, September 23, 2016 at the Westin Chicago Northwest Hotel in Itasca, Illinois. Hosted by MicroCapClub, the Summit utilizes a small group..."/>
First Choice Healthcare Solutions to Present at MicroCap Leadership Summit in Chicago
BriaCell Therapeutics Corp. is pleased to announce that it has entered into an agreement with RK Equity Advisors LLC and TrueNorth Lifesciences LLC for the provision of corporate advisory services. The Agreement is effective until September 30, 2017 and is subject to the approval of the TSX Venture Exchange. Pursuant to the Agreement, RK TruthNorth will assist BriaCell in engaging select members of the international investment..."/>
BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth Lifesciences as Corporate Advisor
Viveve Medical, Inc., a medical technology company focused on women's health, today announced the entry into a distribution agreement for the Viveve System with Melon Ltd., a leading distributor of healthcare and aesthetic products including treatment devices, instruments and cosmetics. Melon Ltd. is based in Tampere, Finland and offers an extensive selection of high-quality products from leading manufacturers in Europe, USA and Israel."/>
Viveve(R) Announces Distribution Agreement for Viveve System With Melon Ltd. in Finland
Varian Medical Systems today announced it has received 510 clearance from the U.S. Food and Drug Administration to market the Nexus DR, a high resolution imaging system for X-ray imaging using a digital X-ray detector. The Nexus DR is designed to replace conventional film techniques, or existing digital systems, in multipurpose or dedicated applications."/>
Varian Medical Systems Receives FDA 510(k) Clearance For Nexus DR Digital X-Ray Imaging System
OvaScience on Wednesday announced inducement awards to its newly appointed chief financial officer, Christophe Couturier and executive vice president, Regulatory, Clinical, Medical Affairs and Quality Assurance, Karen Long under its NASDAQ Listing Rule 5635 (c). The company said Couturier received an option to purchase up to 200,000 shares of common stock and Long received an option to purchase up to 120,000 shares of common stock. The inducement grants..."/>
OvaScience awards stock options to 20 new employees under NASDAQ Listing Rule 5635(c)(4)
Masimo announced today the findings of a study recently presented at the World Congress of Anesthesiologists in Hong Kong. In the study, researchers at Cairo University in Egypt investigated the clinical utility of a Masimo SET ® noninvasive, continuous measurement, PVI ®. In the prospective study of 60 adult patients undergoing major abdominal surgery, Drs."/>
Study on Abdominal Surgical Patients Investigates Clinical Utility of Masimo PVI®
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of data from Phase 2 b and Phase 1 clinical trials of ALD403 for the prevention of migraine as well as preclinical data from a case study of ALD403 and other CGRP-antibodies at the 5th European Headache and Migraine Trust International Congress in Glasgow, Scotland.. “The data presented today..."/>
Alder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress
Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes, today announced that it has entered into an exclusive license agreement with PolyBioCept AB, a corporation organized under the laws of Sweden, and a related clinical trials agreement to sponsor two clinical studies in glioblastoma and pancreatic cancer at the Karolinska University Hospital in Sweden."/>
Lion Biotechnologies Enters Into Exclusive License Agreement With PolyBioCept AB and Clinical Trials Agreement With the Karolinska University Hospital
Extendicare Inc. announced that it has declared a cash dividend of C $0.04 per common share of the Company for the month of September 2016, which is payable on October 17, 2016 to shareholders of record at the close of business on September 30, 2016. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act. Extendicare has a Dividend Reinvestment Plan, which provides Canadian resident holders of Common Shares with the..."/>
Extendicare Announces September 2016 Dividend of C$0.04 per Share
MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug development company, today announced that the Company's management has presented at the Rodman& Renshaw 18th Annual Global Investment Conference and is providing investors with a recorded webcast of its presentation available here: http://www.wsw.com/webcast/rrshq26/register. aspx? conf= rrshq26&page= mbvx&url= http://www.wsw.com/webcast/rrshq26/mbvx/index...."/>
MabVax Therapeutics Provides Webcast Presentation at Rodman & Renshaw Conference
CytoSorbents Corporation, a leader in critical care immunotherapy using its CytoSorb ® blood purification technology to help patients survive sepsis and other life-threatening inflammatory conditions, announced its sponsorship of tonight's sold-out Fifth Annual Sepsis Heroes Gala hosted by the Sepsis Alliance at Arena NYC in New York City. Scheduled to coincide with World Sepsis Day that is organized by the Global..."/>
CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day
Veracyte, Inc. today announced that external researchers will present six posters that reinforce the role of the Afirma Gene Expression Classifier as a new standard of care in thyroid cancer diagnosis at the 86 th Annual Meeting of the American Thyroid Association, being held September 21-25 in Denver. Company scientists will also present data suggesting the potential to further enhance the Afirma GEC's performance by..."/>
Veracyte Announces Data from Seven Afirma® Gene Expression Classifier Studies to Be Presented at the 86th Annual Meeting of the American Thyroid Association
Celsion Corporation today announced that the independent Data Safety Monitoring Board has completed its safety review of data from the first three patient cohorts in the ongoing Phase Ib OVATION Study. Based on the DSMB’ s recommendation, the study will continue as planned and the Company will proceed with dosing in its fourth and final patient cohort at an escalated dose. The OVATION Study is a dose-escalating clinical trial combining GEN-1,..."/>
Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase 1 b multi-dose trial of subcutaneously administered XmAb ® 7195, a potential treatment for allergic disease. "A previously completed Phase 1 a study of intravenous administration of..."/>
Xencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology498 Articles
Consumer Discretionary482 Articles
Industrials292 Articles
Financials282 Articles
Health Care263 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.